In a world of low nearly zero interest rates this poses two risks to CGF:
* nearly no return on the safest bonds
*push into lower grade bonds to get yield (but are responsible for the loss), or move up the risk curve into other higher risk assets.
So market is currently being correct in viewing CGF future earnings with some skepticism in light of current yield opportunities.
But that is also the opportunity, because the market is pricing the shares at a much lower multiple against its bv and NTA (ie the market is forecasting that CGF will not be able to make historical returns on its investment portfolio with reference to historical times).
For myself I now see some middle balance ground whereby the discount in share price to BV and share price NTA have contracted sufficiently that I don't need those historical returns to justify my investment at current market pricing (but I am exposed to loss risk still!!!)
- Forums
- ASX - By Stock
- CGF Strategic Valuation
CGF
challenger limited
Add to My Watchlist
0.19%
!
$8.01

In a world of low nearly zero interest rates this poses two...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.01 |
Change
0.015(0.19%) |
Mkt cap ! $5.534B |
Open | High | Low | Value | Volume |
$7.96 | $8.07 | $7.94 | $14.26M | 1.778M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 658 | $8.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.01 | 60079 | 37 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
53 | 12674 | 8.000 |
32 | 25330 | 7.990 |
13 | 19853 | 7.980 |
10 | 22956 | 7.970 |
9 | 26483 | 7.960 |
Price($) | Vol. | No. |
---|---|---|
8.010 | 49948 | 33 |
8.020 | 43167 | 18 |
8.030 | 16992 | 10 |
8.040 | 43894 | 13 |
8.050 | 13229 | 9 |
Last trade - 15.48pm 26/06/2025 (20 minute delay) ? |
Featured News
CGF (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online